Search

Displaying results 131 - 140 of 190 in total
  1. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).

  2. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  3. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with ...

    Categories: Complex Mixtures
  4. Drug

    MX006

    go.drugbank.com/drugs/DB33934
    Experimental

    MX006 is under investigation in clinical trial NCT07807241 (A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3).

  5. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  6. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  7. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.

  8. Drug

    SIG-205

    go.drugbank.com/drugs/DB18548
    Experimental

    SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer

  9. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times [A31696]. … trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared

  10. Drug

    SIG-207

    go.drugbank.com/drugs/DB18547
    Experimental

    SIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified